Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity
- PMID: 9499111
- PMCID: PMC109550
- DOI: 10.1128/JVI.72.3.2491-2495.1998
Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity
Abstract
We have examined the relationship between coreceptor utilization and sensitivity to neutralization in a primary isolate of human immunodeficiency virus type 1 and its T-cell line-adapted (TCLA) derivative. We determined that adaptation of the primary-isolate (PI) virus 168P results in the loss of the unique capacity of PI viruses to utilize the CCR5 coreceptor and in the acquisition by the TCLA 168C virus of sensitivity to neutralization by V3-directed monoclonal antibodies (MAbs). In experiments wherein infection by 168P is directed via either the CCR5 or the CXCR4 pathway, we demonstrate that the virus, as well as pseudotyped virions bearing a molecularly cloned 168P envelope protein, remains refractory to neutralization by MAbs 257-D, 268-D, and 50.1 regardless of the coreceptor utilized. This study suggests that coreceptor utilization is not a primary determinant of differential neutralization sensitivity in PI and TCLA viruses.
Figures




Similar articles
-
Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1.J Virol. 1998 Sep;72(9):7603-8. doi: 10.1128/JVI.72.9.7603-7608.1998. J Virol. 1998. PMID: 9696861 Free PMC article.
-
Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.J Virol. 2005 Jun;79(11):6957-68. doi: 10.1128/JVI.79.11.6957-6968.2005. J Virol. 2005. PMID: 15890935 Free PMC article.
-
Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.J Virol. 2001 Apr;75(8):3568-80. doi: 10.1128/JVI.75.8.3568-3580.2001. J Virol. 2001. PMID: 11264346 Free PMC article.
-
Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1067-76. doi: 10.1089/088922201300343753. AIDS Res Hum Retroviruses. 2001. PMID: 11485624
-
Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.J Virol. 1998 Dec;72(12):9855-64. doi: 10.1128/JVI.72.12.9855-9864.1998. J Virol. 1998. PMID: 9811721 Free PMC article.
Cited by
-
Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.J Virol. 2001 Jul;75(13):5879-90. doi: 10.1128/JVI.75.13.5879-5890.2001. J Virol. 2001. PMID: 11390589 Free PMC article.
-
Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.J Virol. 1998 Mar;72(3):1886-93. doi: 10.1128/JVI.72.3.1886-1893.1998. J Virol. 1998. PMID: 9499040 Free PMC article.
-
Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.J Virol. 2003 Aug;77(15):8570-6. doi: 10.1128/jvi.77.15.8570-8576.2003. J Virol. 2003. PMID: 12857927 Free PMC article.
-
Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis.J Virol. 2001 Nov;75(22):11146-56. doi: 10.1128/JVI.75.22.11146-11156.2001. J Virol. 2001. PMID: 11602754 Free PMC article.
-
Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.EBioMedicine. 2016 Jun;8:237-247. doi: 10.1016/j.ebiom.2016.04.040. Epub 2016 May 5. EBioMedicine. 2016. PMID: 27428434 Free PMC article.
References
-
- Alkhatib G, Combadiere C, Broder C C, Feng Y, Kennedy P E, Murphy P M, Berger E A. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272:1955–1958. - PubMed
-
- Berger, E. A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11(Suppl. A):S3–S16. - PubMed
-
- Bleul C C, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer T A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382:829–833. - PubMed
-
- Broder C C, Dimitrov D S, Blumenthal R, Berger E A. The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component. Virology. 1993;193:483–491. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous